PAREXEL International Co. (NASDAQ:PRXL) has been given an average recommendation of “Hold” by the twelve analysts that are covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $80.76.
Separately, Zacks Investment Research downgraded PAREXEL International from a “buy” rating to a “hold” rating in a report on Thursday, August 17th.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PRXL. World Asset Management Inc increased its holdings in shares of PAREXEL International by 0.3% in the second quarter. World Asset Management Inc now owns 3,212 shares of the medical research company’s stock worth $279,000 after acquiring an additional 9 shares in the last quarter. 1st Global Advisors Inc. increased its holdings in shares of PAREXEL International by 0.4% in the second quarter. 1st Global Advisors Inc. now owns 5,391 shares of the medical research company’s stock worth $469,000 after acquiring an additional 21 shares in the last quarter. Amalgamated Bank increased its holdings in shares of PAREXEL International by 0.6% in the second quarter. Amalgamated Bank now owns 7,259 shares of the medical research company’s stock worth $631,000 after acquiring an additional 42 shares in the last quarter. Public Employees Retirement System of Ohio increased its holdings in shares of PAREXEL International by 4.5% in the first quarter. Public Employees Retirement System of Ohio now owns 1,713 shares of the medical research company’s stock worth $108,000 after acquiring an additional 73 shares in the last quarter. Finally, Texas Permanent School Fund increased its holdings in shares of PAREXEL International by 0.5% in the second quarter. Texas Permanent School Fund now owns 37,062 shares of the medical research company’s stock worth $3,221,000 after acquiring an additional 169 shares in the last quarter. Institutional investors and hedge funds own 87.45% of the company’s stock.
PAREXEL International (NASDAQ:PRXL) last released its earnings results on Monday, August 28th. The medical research company reported $1.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.94 by $0.08. The company had revenue of $557.20 million during the quarter, compared to the consensus estimate of $537.59 million. PAREXEL International had a return on equity of 19.95% and a net margin of 4.62%. During the same quarter in the previous year, the company posted $0.94 earnings per share.
ILLEGAL ACTIVITY NOTICE: “PAREXEL International Co. (PRXL) Given Average Recommendation of “Hold” by Brokerages” was reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2017/11/27/parexel-international-co-prxl-given-average-recommendation-of-hold-by-brokerages.html.
About PAREXEL International
PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.
Receive News & Ratings for PAREXEL International Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Co. and related companies with MarketBeat.com's FREE daily email newsletter.